Back to Market返回行情

ZBH Zimmer Biomet Holdings, Inc.

USHealthcare
$91.38+2.41%OpenMarket Cap: $17.68B

As of 2026-07-10 14:56

Why ZBH matters now

Zimmer Biomet Holdings, Inc. (ZBH) is a US stock in Healthcare. The latest InvestLog snapshot shows $91.38 with +2.41% on the session and $17.68B in market capitalization; recent performance reads 1-month +2.20% and YTD -2.17%.

The latest financial table shown here is Q1 2026, with revenue of $2.09B, net income of $238.1M, and EPS of $1.22. Investors can compare that operating picture with valuation signals such as P/E 25.69 and FCF yield 10.8%.

The latest indexable market news headline is "Zimmer Biomet (ZBH) is a Top-Ranked Value Stock: Should You Buy?" from Zacks Investment Research.

Additional event context on this page matters because analyst consensus is Hold with a median target of $93.00; recent insider activity includes Yi Sang filing S-Sale. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

25.69

PEG

P/B

1.35

P/S

2.02

EV/EBITDA

10.91

DCF Value

$490.79

FCF Yield

10.8%

Div Yield

1.1%

Margins & Returns

Gross Margin

70.0%

Operating Margin

15.6%

Net Margin

9.1%

ROE

6.0%

ROA

3.4%

ROIC

5.3%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$2.09B$238.1M$1.22
Q4 2025$2.24B$139.5M$0.70
FY 2025$8.23B$705.2M$3.55
Q3 2025$2.00B$230.9M$1.16

Analyst Ratings

Consensus

Hold

Target (Consensus)

$96.33

Target (Median)

$93.00

Target Range

$83.00 - $120.00

Strong Buy: 2Buy: 6Hold: 17Sell: 1Strong Sell: 0
CitigroupNeutral
2026-05-28
Wells FargoEqual Weight
2026-04-29
CitizensMarket Outperform
2026-04-29
StifelBuy
2026-04-29
JP MorganNeutral
2026-04-29

Trading Activity

Insider Trades

Yi Sangofficer: Group President, Asia Pacific
Sell2026-06-02
Yi Sangofficer: Group President, Asia Pacific
Sell2026-06-02
HAGEMANN ROBERTdirector
Sell2026-05-27
HAGEMANN ROBERTdirector
Sell2026-05-27
HIGGINS ARTHUR Jdirector
Sell2026-05-27

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

US

Exchange

Beta

0.47

Zimmer Biomet Holdings, Inc. (ZBH), along with its global subsidiaries, operates as a leading player in the musculoskeletal healthcare sector. The company extends its reach across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. ZBH is responsible for the design, manufacturing, and marketing of a wide array of orthopedic reconstructive solutions, including prominent knee and hip replacement systems. Their offerings also encompass Specialized Enabling Technologies (S.E.T.) products, which cover areas such as sports medicine, biologics, foot and ankle care, extremity treatments, and trauma management. Furthermore, the company provides medical devices and surgical instruments specifically for spinal conditions, alongside products for facial and cranial reconstruction. A unique part of their portfolio includes systems designed to stabilize and fixate chest bones, facilitating recovery or reconstruction following open-heart surgery, traumatic injuries, or congenital chest deformities. The company's product lines also feature a comprehensive range of dental solutions, such as reconstructive implants, prosthetics, and regenerative materials. Additionally, they are involved in robotic surgical systems, general surgical instruments, and bone cements. These advanced products and solutions are primarily utilized to address conditions in patients suffering from disorders or injuries affecting bones, joints, and their associated soft tissues. Zimmer Biomet caters to a broad clientele, including orthopedic, neuro-, and oral surgeons, dentists, hospitals, independent distributors, healthcare suppliers, and various other medical specialists. Their network further encompasses agents, healthcare purchasing organizations, and group buying alliances. Originally established in 1927, the enterprise was initially known as Zimmer Holdings, Inc., before rebranding as Zimmer Biomet Holdings, Inc. in June 2015. Its corporate headquarters are situated in Warsaw, Indiana.